The biotech company — whose vaccine was authorized foremergency use among adults in the U.S.back in December — dosed the first adolescents involved in a new trial (called the KidCOVE study) this week, Moderna said in apress release. The company plans to enroll about 6,750 kids in the ...
1、一些人担心这些疫苗太新,而且没有进行足够的测试和研究。 辉瑞和Moderna的疫苗已经在数千名儿童身上进行了测试,没有造成严重的不良反应。但在数百万人接种疫苗后,偶尔出现了非常罕见的并发症,例如,心肌炎——一种心肌炎症,这也只是在...
Moderna says its COVID-19 vaccine strongly protects kids as young as 12. The company released the preliminary findings Tuesday based on testing on more than 3,700 12- to 17-year-olds in the United States.
The most recent trial forModerna'sCOVID-19 vaccine for children revealed that two doses of its vaccine have a 51% vaccine efficacy for kids younger than 2 and 37% among kids from 2 to 5 years old. These results are something that Moderna's Chief Medical Officer Dr. Paul Burton believes...
Moderna asked the Food and Drug Administration for emergency authorization of a second booster of its COVID-19 vaccine for all adults.
Moderna's booster for kids is simply a smaller dose of the same formulation that is already being distributed for older age groups, and did not need to be pre-ordered. Compared to adults, a smaller share of children will be eligible to get the updated booster, because fewer have gotten th...
When will there be a COVID vaccine for kids? Kids 12 and older can now get a vaccine, but younger is still not available. Learn everything you need to know at U.S. News.
Moderna said it has started the process of obtaining full approval of its COVID-19 vaccine. It will submit data “on a rolling basis over the coming weeks,” which the FDA will scrutinize.
Just this month, Moderna released data on a new vaccine that could potentially offer better protection against multiple variants. The company also announced that it expects to release data on an Omicron-specific vaccine soon. This means that there could be more effective vaccines available as soon...
So far, the FDA has authorized three vaccine options for 2023-2024 — two mRNA vaccines from Moderna and Pfizer, for everyone ages six months and older, and a protein-based non-mRNA shot from Novavax, for everyone ages 12 and older. ...